Home > Healthcare > Drug Device Combination > Therapeutic Systems > Oncolytic Virus Immunotherapy Market

Oncolytic Virus Immunotherapy Market Share

Report ID: GMI8770
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Oncolytic Virus Immunotherapy Market Share

The companies are actively prioritizing R&D efforts to pioneer novel therapies, broaden product portfolios, and fortify market presence. Strategic alliances, partnerships, and acquisitions are prevalent strategies to bolster competitiveness. Moreover, advancements in technology and escalating investments in oncology research are enhancing competition within the market.

Oncolytic Virus Immunotherapy Market Companies

Prominent players operating in the oncolytic virus immunotherapy industry are as mentioned below:

Amgen Inc.
Creative Biolabs
Daiichi Sankyo Company Limited
Genelux Corporation
Oncorus Inc.
Replimune Inc.
Siga Technologies
Sorrento Therapeutics Inc.
TILT Biotherapeutics
Viralytics Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Oncolytic virus immunotherapy market size was USD 302.6 million in 2023 and is expected to register 22.6% CAGR from 2024-2032 owing to the increasing incidence of cancer worldwide, which necessitated the development of novel and effective treatment options.

The herpes simplex virus (HSV) segment is expected to register 22.7% CAGR from 2024-2032 due to its ability to specifically infect and replicate within cancer cells while leaving healthy tissue unaffected.

North America oncolytic virus immunotherapy industry is expected to register 22.3% CAGR from 2024-2032 due to the growing patient population and rising cancer incidences in the region.

Amgen Inc., Creative Biolabs, Daiichi Sankyo Company Limited, Genelux Corporation, Oncorus Inc., Replimune Inc., Siga Technologies, Sorrento Therapeutics Inc., TILT Biotherapeutics, and Viralytics Ltd., are some of the major oncolytic virus immunotherapy companies worldwide.